Metacarpophalangeal Arthroplasty: A 14-Year Nationwide Analysis of Trends and Acute Perioperative Outcomes in Rheumatoid Arthritis and Osteoarthritis

Background: Metacarpophalangeal (MCP) arthroplasty is an established surgical option for end-stage MCP arthritis. We analyzed trends in case volumes and 30-day perioperative outcomes after MCP arthroplasty performed for rheumatoid arthritis (RA) and osteoarthritis (OA). Methods: We used the National Surgical Quality Improvement Program database to identify all MCP arthroplasties performed for RA (n = 216) or OA (n = 452) between 2010 and 2023. Bivariate analysis was used to compare patient demographics, operative characteristics, and 30-day outcomes. We analyzed temporal trends in case volumes using Poisson regression models and trends in patient characteristics using linear regression. Results: Patients with RA were more likely to be female (85% vs 54%) and have a history of smoking (22% vs 10%) and chronic steroid use (58% vs 4%). Patients with OA had more prevalent comorbidities including obesity, diabetes, and hypertension. Patients with RA more frequently required multi-joint replacement, concomitant soft tissue balancing procedures, plastic surgery involvement, and inpatient admission. The annual case volume for OA increased at +5.9% per year ( P < .001), whereas the volume for RA remained steady. The outpatient case volume grew at a rate of +4.6% per year ( P < .001). Both groups had similarly low rates of 30-day complications (0.9% RA, 1.8% OA), readmission (0.5% RA, 1.5% OA), and reoperation (0% RA, 0.9% OA). Conclusions: Despite distinct patient profiles and operative complexity, both OA and RA patients experience low rates of perioperative adverse events after MCP arthroplasty. Osteoarthritis is a growing indication for this procedure, which is increasingly being performed in the outpatient setting.